Sub-Saharan Africa has 36% hypertension prevalence, more than 4 million fewer health workers than it needs, and clinic infrastructure that leaves rural populations traveling hours for a blood pressure reading. At the same time, mobile phone subscriptions cover more than 80% of the population, and smartphone adoption is projected to hit 88% by 2030. Remote photoplethysmography sits at the intersection of these two realities: a technology that turns phone cameras into basic vital sign monitors, deployed in a region that desperately needs accessible health screening but lacks the infrastructure for conventional approaches.
The question isn't whether rPPG could help. It's whether the technology actually works in the conditions where it's needed most.
"NCDs are projected to become the leading cause of death in Sub-Saharan Africa by 2030, with cardiovascular disease accounting for the largest burden. More than 1 million CVD-related deaths occur annually in the region." — Nature Reviews, Digital Health Technology Landscape in Sub-Saharan Africa (2025)
The numbers behind the crisis
The scale of the problem is hard to overstate. According to the WHO's 2023 Global Report on Hypertension, Africa's hypertension prevalence sits at 36%, well above the global average. A 2025 analysis published in BMC Public Health estimated that 74.7 million people in Sub-Saharan Africa currently live with hypertension, a figure projected to reach 125.5 million by the end of the decade. Most of these cases go undiagnosed. In rural areas, the combination of distance, cost, and understaffed facilities means that a blood pressure check, one of the simplest screening procedures in medicine, remains out of reach for tens of millions.
The health worker shortage compounds everything. The WHO estimates a deficit of more than 4 million health workers across the continent. Clinics that do exist often serve catchment areas of thousands with skeleton staff. Community health workers fill some of the gap, but they typically lack diagnostic equipment beyond the most basic tools.
Meanwhile, mobile technology has leapfrogged traditional infrastructure across the continent. A 2025 review in Nature noted that Sub-Saharan Africa effectively skipped landline development entirely, jumping straight to mobile. More than 80% of the population has a mobile phone subscription. Internet penetration remains lower at around 25-37%, but 4G and 5G coverage is expanding rapidly. The phones are there. The question is what they can do.
| Factor | Current state | Projected trajectory |
|---|---|---|
| Hypertension prevalence (Africa) | 36% (WHO, 2023) | 125.5 million affected by 2025-2030 |
| Health worker shortage (SSA) | 4 million+ deficit | Growing with population |
| Mobile phone subscriptions (SSA) | 80%+ coverage | Expanding |
| Smartphone adoption (SSA) | ~46% (GSMA, 2023) | 88% by 2030 |
| Mobile internet penetration | 25% (2023) | 66% by 2030 (4G/5G) |
| CVD deaths in SSA | 1 million+ annually | Projected leading cause by 2030 |
| Average distance to clinic (rural) | Often 1-4 hours travel | Limited new infrastructure planned |
What rPPG actually promises (and what it doesn't)
Remote photoplethysmography works by analyzing subtle color changes in facial skin captured by a standard camera. As blood pulses through vessels near the surface, it produces tiny variations in light absorption that algorithms can translate into heart rate, respiratory rate, and estimates of blood pressure and oxygen saturation. The appeal for global health is obvious: no cuff, no oximeter, no specialized hardware. Just a phone someone already owns.
In controlled settings, the results have been encouraging. Tan et al. (2025) at Singapore General Hospital tested rPPG-based blood pressure and hemoglobin measurement across 200 patients with diverse skin tones and medical comorbidities. Their algorithm achieved a mean absolute percentage error of 7.52% for diastolic blood pressure and 9.52% for systolic, with hemoglobin predictions at 8.52% error. These are reasonable numbers for a screening tool in a clinical environment with consistent lighting and stable internet.
Field conditions in Sub-Saharan Africa are not a clinical environment with consistent lighting and stable internet.
A 2025 multi-site field study by Dasa et al. tested an rPPG blood pressure screening tool (Lifelight) across 306 participants in Kebbi State, Nigeria, all with Fitzpatrick skin types V and VI. The results were sobering. The tool produced readings for 81.4% of participants, but agreement with reference cuff measurements was limited: systolic blood pressure showed a mean absolute error of 15.37 mmHg and diastolic 10.91 mmHg. More critically, sensitivity for hypertension detection was extremely low. Systolic sensitivity was 0.04 overall and dropped to 0.00 for Fitzpatrick type VI participants, meaning the tool missed every single case of elevated systolic blood pressure in the darkest skin tone group.
Specificity was high (0.99 for systolic), which means the tool rarely flagged someone as hypertensive who wasn't. But a screening tool that almost never catches the condition it's screening for is, in practical terms, not a screening tool at all.
The study also found that lower internet bandwidth correlated with higher failure rates (correlation coefficients between -0.51 and -0.69), adding another layer of difficulty for rural deployment where connectivity is weakest.
The equity problem that can't be ignored
The Nigeria study surfaced something the rPPG field has been wrestling with for years: algorithmic performance degrades with darker skin tones. This isn't a minor calibration issue. A sensitivity of 0.00 for hypertension detection in Fitzpatrick type VI participants means the technology, as currently implemented in at least one commercial application, would provide false reassurance to the population most at risk.
This matters because Sub-Saharan Africa, where the technology is arguably most needed, is also where the population overwhelmingly has darker skin tones. Any rPPG system deployed for population health screening in the region must perform equitably across the full range of skin pigmentation. The research makes clear that current algorithms have not reached that threshold.
Dasa et al. noted an interesting disconnect: despite the poor diagnostic performance, 70% of patients rated the tool's accuracy favorably, and more than 90% of staff expressed willingness to adopt it. This perception-performance gap is concerning. If communities trust a tool that misses most hypertensive cases, the consequences could be worse than having no screening at all, because people walk away believing their blood pressure is fine when it isn't.
Where the technology does work (and where it's heading)
None of this means rPPG is a dead end for global health. It means the technology is at an earlier stage than some deployments have assumed.
Heart rate measurement via rPPG is substantially more mature than blood pressure estimation. The underlying signal, pulse rate extracted from facial color variation, is more robust and less affected by the algorithmic challenges that plague blood pressure prediction. For basic cardiovascular screening, triage, and population-level heart rate monitoring, smartphone-based rPPG is already showing real utility.
Several research directions could address current limitations:
- Training data diversity. Most rPPG algorithms were developed using datasets that skew heavily toward lighter skin tones. Expanding training sets to include proportional representation of Fitzpatrick types V and VI is a prerequisite for equitable performance.
- Offline capability. The bandwidth dependency identified in the Nigeria study points to the need for edge processing, running algorithms entirely on-device rather than relying on cloud connectivity.
- Ambient light adaptation. Field conditions involve variable lighting that clinical settings don't. Algorithms that can compensate for outdoor lighting, low-light conditions, and inconsistent illumination will be necessary for real-world deployment.
- Validation in target populations. The gap between clinical validation (often conducted in well-equipped hospitals in high-income countries) and field performance in low-resource settings needs to close through dedicated field trials.
Circadify has developed smartphone-based rPPG technology and is actively working on deployment for low-resource health settings. The company's recent field trial in Uganda demonstrated high acceptability among community members, though the broader industry challenge of ensuring accuracy across all skin tones and field conditions remains an area of ongoing development.
What comes next for rPPG in global health
The WHO launched its Global Initiative on Digital Health in 2024, signaling institutional recognition that mobile technology will play a growing role in healthcare delivery across developing regions. Sub-Saharan Africa, where digital technology is already ranked among the top five business sectors by investment and where mHealth has shown documented success in maternal health, oncology coordination, and infectious disease management, is a natural proving ground.
But the lesson from the Nigeria field study is that "promising technology" and "deployable screening tool" are separated by a significant gap. Bridging it requires honest assessment of where algorithms fail, investment in diverse training data, and field validation that matches the conditions where the technology will actually be used. High specificity doesn't help if sensitivity is near zero. Community acceptability doesn't help if the readings aren't reliable.
A smartphone that can reliably screen for hypertension in a rural village, operated by a community health worker with minimal training, would change the math on cardiovascular disease prevention across an entire continent. The technology exists in principle. Making it work equitably in practice is the work that still needs to happen.
Frequently Asked Questions
Can rPPG technology work on darker skin tones?
Current research shows mixed results. A 2025 multi-site field study in Nigeria found critically low sensitivity for hypertension detection in Fitzpatrick type VI participants, while other studies have demonstrated feasibility across diverse skin tones in controlled clinical settings. Algorithmic improvement for darker skin remains one of the most important active areas of rPPG research.
What vital signs can rPPG measure using a smartphone?
Remote photoplethysmography can estimate heart rate, blood oxygen saturation (SpO2), respiratory rate, and blood pressure using only a standard smartphone camera. Some newer algorithms also attempt hemoglobin concentration estimation, with early results showing mean absolute percentage errors around 8.5% in clinical settings.
Is rPPG accurate enough for clinical screening in Africa?
Not yet for all applications. Heart rate measurement is relatively mature, but blood pressure screening in field conditions still shows significant accuracy gaps, particularly for darker-skinned populations and in areas with poor internet connectivity. The technology needs further algorithmic development and field validation before it can be recommended for population-level screening.
Why is smartphone-based vital sign monitoring relevant for Sub-Saharan Africa?
The region has a health worker shortage exceeding 4 million, hypertension prevalence of 36%, and limited clinic infrastructure that forces rural populations to travel hours for basic screening. With smartphone adoption projected to reach 88% by 2030, camera-based vitals could extend basic health screening to populations that currently have no access at all.
Related Articles
- What is rPPG Technology? — How remote photoplethysmography works and the research behind it.
- rPPG Accuracy Across Diverse Populations — Research on how rPPG performs across different skin tones and demographics.
- Community Voices: What Happened When We Brought Contactless Vitals to Uganda — Real reactions from community members in Uganda after using smartphone-based rPPG.